The 2013 American College of Cardiology/American heart association guidelines for the treatment of dyslipidemia: Mind the gaps!

Current Medical Research and Opinion

Volumn 30, Issue 9, 2014, Pages 1701-1705

  Athyros, Vasilios G ^a,b   Katsiki, Niki ^a,b   Karagiannis, Asterios ^a,b   Mikhailidis, Dimitri P ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

ACC AHA guidelines; Cardiovascular disease; Dyslipidemia; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOLOGY; DYSLIPIDEMIAS; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; RISK ASSESSMENT; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIOLOGY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84906840082     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.924488     Document Type: Review

References (40)

1. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of New Cholesterol Guidelines to a Population-Based Sample. N Engl J Med 2014: published online 19 March 2014, doi: 10.1056/NEJMoa1315665
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720-32
3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013: published online 7 November 2013, doi: 10.1016/j.jacc.2013.11.002
4. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013: published online 12 November 2013, doi: 10.1016/j.jacc.2013. 11.005
5. American Heart Association, American College of Cardiology. 2013 Prevention Guidlines Tools: CV risk calculator. Available at: http://my.americanheart. org/professional/StatementsGuidelines/ Prevention%20Guidelines/PreventionGuidelines-UCM-457698-SubHomePage.jsp. Last accessed 1 May 2014
6. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72-4
7. Ridker PM, Cook NR. Statin guidelines and the prevention of cardiovascular disease. Lancet 2013;382:1762-5
8. Ridker PM1, Cook NR2. Refining the American guidelines for prevention of cardiovascular disease-authors' reply. Lancet 2014;383:600
9. Keaney Jr JF, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med 2014;370:275-8
10. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl):1-34K
11. Miller M, Cannon CP, Murphy SA, et al.; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
12. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
13. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25:567-79
14. European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010, 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
15. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
16. Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a 'coronary heart disease equivalent': an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-7
17. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
18. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95
19. Mankad R, Gabriel SE. Rheumatoid arthritis: treating cardiovascular risk in RA requires multidisciplinary care. Nat Rev Rheumatol 2014: published online 18 March 2014, doi: 10.1038/nrrheum.2014.37
20. Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations. Angiology 2013;64:572-5
21. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2012;57:1109
22. Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014 in press
23. Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial. J Am Coll Cardiol 2013;63:430-3
24. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
25. Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 2013;131:1427-34
26. Navarese EP1, Szczesniak A, Kolodziejczak M, et al. Statins and risk of newonset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2014;14:79-87
27. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus-a matter for debate. Nat Rev Endocrinol 2012;8:133-4
28. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010;11:1965-70
29. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52
30. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80
31. Galatti L, Polimeni G, Salvo F, et al. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006;26:1190-2
32. FDA. Crestor (rosuvastatin calcium) tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ucm200635. htm. Last accessed 1 May 2014
33. Ahn P, Min HJ, Park SH, et al. Rhabdomyolysis and acute kidney injury associated with hypothyroidism and statin therapy. Endocrinol Metab (Seoul) 2013;28:331-4
34. Hilton-Jones D. Myopathy associated with statin therapy. Neuromuscul Disord 2008;18:97-8
35. American Heart Association. Lifestyle Changes and Cholesterol. Available at: http://www.heart.org/HEARTORG/Conditions/Cholesterol/ PreventionTreatmentofHighCholesterol/Lifestyle-Changes-and-Cholesterol-UCM- 305627-Article.jsp. Last accessed 1 May 2014
36. Fruchart JC, Davignon J, Hermans MP, et al. Residual Risk Reduction Initiative (R3i). Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014;13:26-42
37. Ray KK, Kastelein JJ, Matthijs Boekholdt S, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-8
38. American Diabetes Association. Treatment targets. Diabetes Care 2014;37(Suppl 1):S16-80
39. American Association of Clinical Endocrinologists. Available at: http://www.aace.com. Last accessed 1 May 2014
40. The European Athersclerosis Society. New guidlines in USA: How do they compare with the EAS/ESC guidelines for the management of dyslipidaemia? Available at: http://www.eas-society.org/Newsletter-Archive.aspx?newsId= 316. Last accessed 1 May 2014